-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

A Rare Day in the Community Hematology Clinic: Interesting Cases in Classical Hematology

Sponsor: Agios, Novartis Oncology
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Diseases, Adverse Events, Study Population
Friday, December 8, 2023: 3:00 PM-6:00 PM
Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)
Chair:
Morag Griffin, FRCPath, MRCP, St James's University Hospital
Disclosures:
Griffin: Biocryst: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Sobi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Alexion, AstraZeneca Rare Disease: Honoraria, Membership on an entity's Board of Directors or advisory committees; Regeneron Pharmaceuticals: Consultancy; Apellis: Other: educational grant support .
Speaker:
Michael R. DeBaun, MD, MPH, Vanderbilt University Medical Center
Disclosures:
DeBaun: Novartis, Forma, Vertex: Consultancy, Other: Consulting.
On Demand program will be available here January 8, 2024.

Sickle cell disease (SCD) is the world’s most common genetic disease, affecting more than 3 million people worldwide. Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired form of intravascular hemolysis with a worldwide incidence of five to six cases per million people and a prevalence of 16 cases per million people. In this live symposium, 2 experts in the field of SCD and PNH will delve into the identification, diagnosis, treatment nuances, and overall management of these 2 classic hematologic malignancies using case studies as a practical guide. Additionally, our panel will discuss the implications of health inequities and how to address more accessible, equitable, cost-effective, and person-centered care for patients affected with PNH and SCD.

See more of: Friday Satellite Symposia
<< Previous Application | Next Application >>